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Abstract
Introduction: In general, genomic signatures of breast cancer subtypes have little or no overlap owing to the
heterogeneous genetic backgrounds of study samples. Thus, obtaining a reliable signature in the context of isogenic
nature of the cells has been challenging and the precise contribution of isogenic triple negative breast cancer (TNBC)
versus non-TNBC remains poorly defined.
Methods: We established isogenic stable cell lines representing TNBC and Human Epidermal Growth Factor
Receptor 2 positive (HER2+) breast cancers by introducing HER2 in TNBC cell lines MDA-MB-231 and MDA-
MB-468. We examined protein level expression and functionality of the transfected receptor by treatment with an
antagonist of HER2. Using microarray profiling, we obtained a comprehensive gene list of differentially expressed
between TNBC and HER2+ clones. We identified and validated underlying isogenic components using qPCR and
also compared results with expression data from patients with similar breast cancer subtypes.
Results: We identified 544 and 1087 statistically significant differentially expressed genes between isogenic TNBC
and HER2+ samples in MDA-MB-231 and MDA-MB-468 backgrounds respectively and a shared signature of 49
genes. By comparing results from MDA-MB-231 and MDA-MB-468 backgrounds with two patient microarray
datasets, we identified 17 and 22 common genes with same expression trend respectively. Additionally, we identified
56 and 78 genes from MDA-MB-231 and MDA-MB-468 comparisons respectively present in our published RNA-seq
data.
Conclusions: Using our unique model system, we have identified an isogenic gene expression signature between
TNBC and HER2+ breast cancer. A portion of our results was also verified in patient data samples, indicating an
existence of isogenic element associated with HER2 status between genetically heterogeneous breast cancer
samples. These findings may potentially contribute to the development of molecular platform that would be valuable
for diagnostic and therapeutic decision for TNBC and in distinguishing it from HER2+ subtype.
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Introduction
Breast cancer is the most commonly diagnosed cancer
among women worldwide [1]. In the United States, one out of
every three cases of cancer diagnosed in women is that of the
breast and associated malignancy is the second largest causes
of cancer deaths [2]. Although breast cancer is claimed to have
a higher prevalence among women from the developed part of
the world, this statistics is rapidly changing. The incidence of
the disease is on the rise even in developing countries, where
the cumulative risk for women below 75 years of age and
mortality rate is almost equivalent to the rate found in the
developed countries [1]. The phenotypic and clinical
manifestations of the disease vary widely among women, and
various cancer subtypes show wide range of responses to
different treatment modalities. The stage, grade and status of
three therapeutically relevant receptors, estrogen receptor
alpha (ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2) are the main determinants of
tumor response to most of the current treatments, and
therefore, are the major factors in planning optimal therapy [3].
In the past decade, we have witnessed an active
investigation of heterogeneity of breast cancer at the molecular
level through various high throughput approaches. Derived
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from a large collection of tumors, these studies have classified
breast cancer into five major subtypes based on expression
pattern of an ‘intrinsic gene set’ signature [4,5]. These subtypes
include luminal A and B, basal-like, HER2 overexpressing and
normal breast like and are named according to the markers
expressed by the corresponding cell types. These molecular
classes not only differ in the expression levels of ER, PR and
HER2 but also in disease prognosis [6]. The luminal subtypes
show higher expression of ER and have a favorable prognosis
and basal-like tumors have absence or low levels of the three
receptors and in general, exhibit poor prognosis. These studies
point to the likelihood that different breast cancer subclasses
might stem from different cellular types based on origin. Over
the years, a number of studies have validated and refined such
signatures [7,8,9,10,11,12,13,14]. It is generally believed that
different breast tumor subtypes represent distinct disease
entities and may require personalized treatment modalities for
an effective outcome. Despite multitude of studies on breast
cancer expression signatures and their proclaimed robustness,
the biological relevance of these signatures remains to be
firmly established and this is an area for further improvement.
The status of ER, PR and HER2 is routinely assessed prior
to deciding treatment options in general for breast cancer. Two
of the most common treatment regimens include anti-estrogens
like Tamoxifen or Fulvestrant or aromatase inhibitors for ER+
tumors and monoclonal antibody Herceptin (Trastuzumab) for
HER2+ tumors. However, for TNBC that lacks both ER and
HER2, there is no targeted therapy so far and the only option is
non-specific and highly toxic chemotherapy or radiation therapy
[15]. Unlike other subtypes of breast cancer, TNBC commonly
affects younger (< 50 years) pre-menopausal women. It is a
very aggressive form of breast cancer with majority of the
deaths occurring within the first five years of diagnosis [16].
The relapse rates and the prognoses for these patients are
very poor even after treatment [17]. Therefore there is a
pressing need and growing research interest to understand
how TNBC, which comprises approximately 15% of all breast
cancers, differs from other subtypes [18].
Most comparative studies of breast cancer subtypes
consider clinical or biological variables for classifying samples.
However, these studies fail to account for the heterogeneity of
samples within subtypes as well as clonal origin of most
tumors. For example, although cultured TNBC cell lines
routinely used in the laboratory are similar in the context of
receptor status, they are distinct in terms of their genotypes.
Human breast tumors similarly show significant genetic
heterogeneity. Thus, studies involving samples from TNBC and
non-TNBC cancer subtypes with diverse genetic background
[19] can’t be directly compared, especially when most breast
cancers start as clonal in the initial stage of tumor formation. To
mitigate this issue and to eliminate variability due to different
genetic backgrounds, we established an isogenic cell line
model system representing two common breast cancer
subtypes. We stably transfected empty vector or HER2 in two
TNBC cell lines MDA-MB-231 and MDA-MB-468 and created
isogenic TNBC or non-TNBC differing in the status of HER2.
After initial characterization of these isogenic cell lines, we
performed a microarray-based gene expression profiling to
deduce the signatures of TNBC compared to non-TNBC
isogenic cells, and searched resulting signatures in
compactable publically available data sets.
Methods
Generation of Stable Clones
Triple-negative breast cancer MDA-MB-231 and MDA-
MB-468 cells (ATCC) were chosen for stable clone generation.
Origin of the cell lines have been described previously [19].
Transient transfections with 2.5-10 µg of plasmid per reaction
with Fugene transfection reagent (Roche Ltd.) were used to
optimize transfections. Using optimal conditions, the two cell
lines were transfected with each of the two plasmids; pcDNA
3.1a and HER2. Cells were cultured using Dubelcco’s Modified
Eagle Medium/ Ham’s F12 50:50 (DMEM/F-12) mix
(Mediatech) supplemented with 10% FBS (Atlanta Biologics)
and 1% Antibiotics (Gibco) and kept at an incubator maintained
at 37°C and 5% CO2. The transfected cells were then treated
with 0.5µg/ml of G418 over several weeks to select for the cells
containing the plasmids. Multiple plates were then pooled and
selected for 2-3 more weeks to generate multiple stable clones.
Proteins from these plates were harvested using RIPA buffer
and 50µg of protein were loaded on an 8% SDS-PAGE gel &
transferred on a nitrocellulose paper (Biorad). TNBC and
HER2+ clones generated on one type of cell line were included
in one gel along with negative & positive controls. Protein from
parental (untransfected) cell line SKBR3 (HER2-positive) cell
lines were used as negative and positive controls respectively.
The membrane was then blotted with HER2 antibody (Bethyl)
and was reprobed with vinculin antibody (Sigma) as a protein
loading control. Protein in the membrane was then detected
using ECL reagent (GE Healthcare) and exposed onto an
autoradiography film (Hyblot CL). Clones showing highest
expression of HER2 protein compared to negative control were
selected for further experiments. Our experimental studies
involved established in vitro immortalized human breast cancer
cell lines and secondary data from in-house RNA-sequencing
study and public microarray repository of human patient
samples. Therefore, an ethical approval was not needed.
Flow Cytometry
Cells were plated in duplicates in 60 cm dishes with
complete media and allowed to grow at 37°C and 5% CO2 until
the cells reached desired confluency. After one wash with PBS,
the cells were treated with 0.5M EDTA to detach cells, followed
by centrifugation at 500 x g for 5 minutes. They were then
washed thrice with PBS buffer containing 0.5% BSA and
resuspended in the same buffer to get approximately 4X10^6
cells/ml. From this, about 10^5 cells in a reaction volume of 25µl
were taken and added to a tube containing 10µl of
Phycoerythrin (PE) conjugated anti-human HER2 antibody
(R&D Systems). For isotype control, 10 µl of PE-conjugated
mouse IgG2B reagent (R&D Systems) was added to 10^6 cells.
The mixture was incubated for about 45 minutes at 4°C. The
cells were washed twice with PBS buffer containing 0.5% BSA
and resuspended in 200-400µl of PBS for flow cytometry
analysis. For experiments involving Herceptin treatment, two
Isogenic Signature of Breast Cancer Subtypes
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HER2 and a TNBC clone were plated in 60 cm dishes. Starting
the next day the cells were serum starved for 24 hours. After
starvation, cells were treated with 10nM Herceptin and
incubated at 37°C and 5% CO2 for 16 hours. Cells were then
collected and prepared for flow cytometric analysis as
mentioned above.
Confocal Microscopy
Cells were plated in 60 cm dishes with complete media, and,
starting the next day, serum starved for 24 hours. After
starvation, cells were treated with 10nM Herceptin and
incubated at 37°C and 5% CO2 for 16 more hours. After one
wash with PBS, the cells were trypsinized and plated over
glass cover slips placed on culture plates. The cells were then
fixed in 4% paraformaldehyde for 20 minutes at room
temperature, permeabilized for 5-15 min with 0.1% triton-
X-100. Indirect immunofluorescence technique was used to
examine the cells. The cells were blocked with 5% normal goat
serum for half an hour and then incubated with HER2 antibody
(1:50 dilution) for 2 hours at room temperature, washed three
times with PBS, and incubated with Alexa Fluor 546-labeled
secondary antibody (Molecular Probes). We used DAPI
(Molecular Probes) to stain DNA. Confocal microscopy was
performed using a Zeiss laser-scanning confocal microscope.
Gene Expression Profiling Using Microarray
Triplicates of one each of TNBC and HER2+ isogenic clones
in both cell lines were plated and grown to 60-70% confluency
in complete media containing G418. RNA was extracted using
TRIZOL reagent (Invitrogen) according to manufacturer
recommendations and quantified using a Nanodrop. Using
RNeasy Mini Kit (Qiagen, Valencia, CA), RNA was purified and
its integrity was tested using Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). After RNA cleanup and
labeling, the samples were hybridized onto an Affymetrix
Human Exon 1.0 ST array chip and washed according to
manufacturer’s protocol. The chips were then scanned to
measure signal intensities. Resulting raw files were
preprocessed using Robust Multi-array Average (RMA)
algorithm, filtered and normalized by quantile technique using
Gene Spring GX 10.0 (Agilent Technologies Inc.). Unpaired t-
test was used to identify statistically significant differentially
expressed genes between TNBC and HER2+ (p-value ≤0.05
and fold-change ≥1.5) in each cell line background. Benjamini
and Hochberg method was used for multiple testing correction.
Validation by quantitative Real Time PCR
RNA was extracted from the cells using TRIZOL reagent
(Invitrogen) and 1µg was used for cDNA synthesis using
Superscript III reverse transcriptase kit (Invitrogen) with oligodT
method. Using SYBR Green RT PCR mastermix (Biorad), the
qPCR reaction was set up in duplicates using 1µl of the cDNA
as a template. 18S was used as a housekeeping control. The
fluorescence detection and measurements were taken using
Applied Biosystems thermal cycler. The relative expression
levels of candidate genes for each cell line were calculated
after normalization with control. The resulting values were then
averaged and plotted as bar plot. Standard error (S.E.) was
included in the graph. Two tailed unpaired student’s t-test was
used for statistical analysis of the difference in expression
between TNBC and HER2 clones.
Comparison with Microarray from GEO
Among the breast cancer microarray datasets with patient
samples in Gene Expression Omnibus (GEO) [20], studies
employing GPL96 (Affymetrix Human Genome U133A Array)
and GPL570 platforms (Affymetrix Human Genome U133 Plus
2.0 Array) were searched. Datasets containing samples from
patients with untreated tumors or tumors prior to treatment
were chosen. Samples representing the subtypes included in
our study were selected based on the clinical annotation and
information provided by Lehmann et al in identifying tumor
subtypes of the samples [21]. Two different datasets
representing each of the two microarray platforms (GPL96 and
GPL570) were compiled for comparison with our results.
Datasets we included in our study were GSE7390, GSE2603,
GSE3494, GSE2990, GSE2034, GSE11121, GSE1561 and
GSE20194 from GPL96 platform. Similarly datasets from
GPL570 platform were GSE7904, GSE2109, GSE19615 and
GSE12276. Tables S1A and B provide information about the
GEO datasets that were selected and number of samples for
each subtype included from each dataset.
Gene Ontology and Pathway Analysis
The gene ontology (GO) and pathway analysis of the genes
with deregulated expression and splicing was analyzed using
Database for Annotation, Visualization and Integrated
Discovery (DAVID) [22,23]. The enrichment of GO terms
comprising molecular process and biological functions were
identified. A p-value of 0.05 was considered significant for the
results.
Results
Establishing Isogenic Stable Cell line Models
We created an isogenic model system for comparative study
of two major breast cancer subtypes by stably transfecting
empty vector or HER2 plasmids into TNBC cell lines MDA-
MB-231 and MDA-MB-468. Protein expression levels of the
reconstituted receptor in the pooled stable clones were
measured using western blot. Results showed multiple clones
in which the levels of HER2 in corresponding stable cell lines
were higher than that in TNBC clones. Representative
immunoblot of selected clones in each background showing
high levels of HER2 in comparison to parental cell lines and
TNBC clones are shown in Figure 1A. Surface expression of
HER2 in TNBC and HER2+ clones was examined using flow
cytometry. As shown in Figure 1B, HER2+ clones showed a
larger population of cells with high expression of HER2
compared to TNBC clones.
Biological Characterization of TNBC and HER2+
Isogenic Clones
Next we examined whether the transfected HER2 receptor is
responsive to anti-HER2 monoclonal antibody Herceptin.
Isogenic Signature of Breast Cancer Subtypes
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Treatment with Herceptin resulted in downregulation of surface
expression of HER2 in the receptor positive clones in both cell
lines as noted in the flow cytometry results (Figure 2).
Numerical value in blue in the lower right of the flow cytometry
measurements for each condition is the percentage of cells
with high expression of HER2 as measured in that quadrant.
Figure 1.  Expression of HER2 in stable isogenic clones.  Expression level of HER2 in the receptor positive clones (HER2#1 and
9 in MDA-MB-231 and HER2#1, 2 and 3 in MDA-MB-468) was higher than in TNBC clones (pcDNA) in both cell line backgrounds.
A) Representative western blot of stable cell lines showing HER2 expression. Two and three HER2 clones were selected for
experiments based on initial assessment of receptor expression levels in HER2 clones compared to TNBC. 50µg of whole cell
lysate was used for immunoblotting. Untransfected parental cell line (untrans.) was used as a negative control and HER2
overexpressing cell line SKBR3 was used as positive control (+ve control). Vinculin was used as a protein loading control. Black
dotted lines indicate intervening lanes that have been removed. Total protein expression in HER2+ clones were higher than in
TNBC clones and almost comparable to levels expressed in the positive control. B) Flow cytometry results of surface expression of
HER2 in TNBC and HER2 positive clones. The percentage of cells with higher expression of HER2 is more in HER2 positive clones
compared to TNBC clones. Numbers in blue indicate the percentage of the cells in the lower right quadrant. Untrans, untransfected;
+ve, positive.
doi: 10.1371/journal.pone.0074993.g001
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The levels of the receptor tyrosine kinase after treatment of
HER2+ clones with Herceptin were almost similar to the levels
seen in TNBC clones. Congruent results were obtained using
confocal microscopy as shown in Figure S1A-B.
Gene Expression Analysis
Following biological characterization, we carried out gene
expression profiling of TNBC and HER2+ clones in MDA-
MB-231 and MDA-MB-468 background using an Affymetrix
human exon array. Pairwise differential expression between
the TNBC and HER2+ clones in both backgrounds were
performed. A schematic diagram of differential expression
analysis is illustrated in Figure 3A. In brief, pairwise differential
expression analyses between the TNBC and HER2+ clones
were performed individually for each cell line background and
genes upregulated and downregulated in TNBC were
identified. Gene lists from both backgrounds were then
compared to delineate common genes with a similar
expression pattern. Results from our studies were also overlaid
with data from patient studies with similar breast cancer
subtypes. A heatmap of the statistically significant differentially
expressed genes (p. value ≤0.05 and fold change ≥1.5) in both
backgrounds are shown in Figure 3B. Comparison of TNBC
versus HER2+ clones in MDA-MB-231 cell lines resulted in 544
differentially expressed genes, 210 up and 332 downregulated.
Similar comparison in the MDA-MB-468 cell lines also provided
1087 differentially expressed genes, 660 up and 426
downregulated (Figure 3C, Table S2). Between the two TNBC
versus HER2+ comparisons, there were 49 genes that were
common following same trend of regulation, with 18
upregulated and 31 downregulated genes (Figure 3C, Table 1).
Based on biological significance and association with breast
cancer, 34 candidates were selected from the differential
expression gene lists for validation using qPCR. Among these
30 genes exhibited positive results showing a similar trend of
expression levels as in the microarray analyses. Some of the
candidates include Lumican (LUM), lipase, endothelial (LIPG),
and Lysyl oxidase homolog 2 (LOXL2), Cathepsin B (CTSB)
(Figure 4A-D). LUM is upregulated while LIPG is
downregulated in the TNBC clones as compared to the HER2+
clones from MDA-MBA-231 and MDA-MB-468 cell lines,
respectively. Moreover, LOXL2 and CTSB are downregulated
in the TNBC clones as compared to the HER2+ clones in both
cell lines. The difference in expression levels were significant
for LIPG (p <0.01), LOXL2 in MDA-MB-231(p < 0.05) and
MDA-MB-468 cell lines (p < 0.01), and for CTSB in MDA-
MB-468 cells (p < 0.01).
Figure 2.  Downregulation of HER2 in TNBC and HER2+ve clones with Herceptin treatment.  Flow cytometry was used to
examine the levels of surface expression of HER2 in TNBC and HER2+ve clones in A) MDA-MB-468 and B) MDA-MB-231
backgrounds with or without Herceptin treatment. One TNBC and two HER2 clones in each cell line were treated with 10nM 4D5
after 24hr starvation. The percentage of cells with high expression of HER2 is decreased in HER2 positive clones after treatment
with Herceptin. Numbers in blue indicate the percentage of cells in the lower right quadrant.4D5,Herceptin.
doi: 10.1371/journal.pone.0074993.g002
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Figure 3.  Gene expression profiling of stable clones using microarrays.  A) A flow diagram for analysis of gene expression
data from microarray experiment. Pairwise comparison of differential expression between TNBC and HER2+ clones are computed
using a p value of 0.05 and Fold change 1.5. B) Heatmap showing clustering of differentially expressed genes between TNBC and
HER2+ve samples. C) Venn diagram showing genes that are upregulated or downregulated in each cell line. Overlapping genes
between the two cell lines are shown in the intersection of the Venn diagram.
doi: 10.1371/journal.pone.0074993.g003
Isogenic Signature of Breast Cancer Subtypes
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LUM belongs to the small leucine rich proteoglycan family of
proteins that is involved in collagen fibril organization, in growth
and migration of epithelial cells, in tissue repair, and in the
progression of breast tumor. Higher expression of LUM was
Table 1. Deregulated genes in TNBC compared to HER2+
in MDA-MB-231 and MDA-MB-468 backgrounds.
Regulation Gene Description
Up CASP2 caspase 2, apoptosis-related cysteine peptidase
Up CCDC69 coiled-coil domain containing 69
Up CDH1 cadherin 1, type 1, E-cadherin (epithelial)
Up COBLL1 COBL-like 1
Up CTSH cathepsin H
Up FNBP1L formin binding protein 1-like
Up KAL1 Kallmann syndrome 1 sequence
Up KIAA1161 KIAA1161
Up LRIG1 leucine-rich repeats and immunoglobulin-like domains 1
Up PQLC3 PQ loop repeat containing 3
Up PTGS1
prostaglandin-endoperoxide synthase 1 (prostaglandin
G/H synthase and cyclooxygenase)
Up SCARA3 scavenger receptor class A, member 3
Up SELENBP1 selenium binding protein 1
Up TMEM87B transmembrane protein 87B
Up TRIB2 tribbles homolog 2 (Drosophila)
Down AGPAT5
1-acylglycerol-3-phosphate O-acyltransferase 5
(lysophosphatidic acid acyltransferase, epsilon)
Down AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9
Down AHNAK2 AHNAK nucleoprotein 2
Down ALDH1A3 aldehyde dehydrogenase 1 family, member A3
Down CA9 carbonic anhydrase IX
Down CTSB cathepsin B
Down DPYSL2 dihydropyrimidinase-like 2
Down DUSP1 dual specificity phosphatase 1
Down EDN1 endothelin 1
Down EIF3E eukaryotic translation initiation factor 3, subunit E
Down ERRFI1 ERBB receptor feedback inhibitor 1
Down EXOSC2 exosome component 2
Down GDF15 growth differentiation factor 15
Down GNA15
guanine nucleotide binding protein (G protein), alpha 15
(Gq class)
Down GPRC5A
G protein-coupled receptor, family C, group 5, member
A
Down IRAK3 interleukin-1 receptor-associated kinase 3
Down LOX lysyl oxidase
Down NOG noggin
Down NOV nephroblastoma overexpressed
Down NRK Nik related kinase
Down PAPPA pregnancy-associated plasma protein A, pappalysin 1
Down PRSS23 protease, serine, 23
Down RGS2 regulator of G-protein signaling 2, 24kDa
Down TMEM45B transmembrane protein 45B
Down TNFRSF10D
tumor necrosis factor receptor superfamily, member
10d, decoy with truncated death domain
Down TNFRSF11B tumor necrosis factor receptor superfamily, member 11b
Down XK X-linked Kx blood group (McLeod syndrome)
doi: 10.1371/journal.pone.0074993.t001
found in breast cancer stroma as compared to the normal
tissue and was found to be associated with low levels of
estrogen receptor and higher tumor grade [24].
LIPG is a member of the triglycerides lipase family and is
thought to be associated with metabolism of lipoproteins in
endothelial cells. It was found to be one of the lipid
metabolizing enzymes whose expression correlated with HER2
overexpression in a breast cancer cell line [25].
A member of the lysyl oxidase family, LOXL2, is of
paramount importance in the extracellular matrix remodeling by
crosslinking collagen with elastin. It is also found to play an
important role in the development, tumor progression, epithelial
to mesenchymal transition (EMT) and senescence. It is
associated with distant metastasis and poor survival rates [26].
CTSB is a member of the lysosomal cysteine proteinases
and is involved in protein degradation. It is found to play an
important role in tumor invasion and metastasis and also
considered a prognostic marker in an aggressive form of breast
cancer known as the inflammatory breast cancer [27,28]. CTSB
along with CTSL was found to be overexpressed in HER2
positive cancers and is an important mediator of tumor invasion
in this subtype of breast cancer [29].
Next, we were interested in biological contextualization of the
differentially expressed gene list that we obtained from
microarray analysis. We did a gene ontology analysis using
DAVID to investigate if any functional categories were enriched
in our data. The top ten biological processes and molecular
function of differentially expressed genes between the TNBC
and HER2+ clones in each background are depicted in Table
S3A-D, respectively. Biological functions like cell signaling,
adhesion, regulation of apoptosis and proliferation were
common themes for genes upregulated in TNBC in both cell
lines. Similarly, shared themes like response to wounding and
organic substance were common categories in genes
downregulated in TNBC.
Comparison with Data from Patient Samples
We next compared the differential gene expression signature
derived from the isogenic studies with data obtained from
patients with breast cancer of similar subtypes, i.e. TNBC vs.
HER2+. We initially aligned our data to individual datasets from
independent studies. However, due to variability in the overlaps
between our results and the datasets being compared and
small sample size in many of these datasets, we switched to a
different approach. We sought to create a super-dataset from
various microarray studies by different groups of investigators.
We identified several studies from Gene Expression Omnibus
(GEO) repository that contained microarray data from breast
cancer patients that hadn’t undergone any treatment. During
curation of datasets, we only included samples from studies
that used two most common Affymetrix platforms in GEO
(GPL96 and GPL570). Although the sample size of dataset
containing samples from GPL96 platform was bigger, the
probes included in the platform were almost half of those
included in the GPL570 platform. Therefore, we created two
independent super-datasets that included samples
corresponding to our subtypes from the two platforms.
Schematic diagram for curation of samples from GEO is shown
Isogenic Signature of Breast Cancer Subtypes
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Figure 4.  Validation of microarray results.  Selected genes showing significant deregulation (p-value ≤0.05 and fold change ≥
1.5) of mRNA expression between TNBC and HER2 clones from microarray data were validated using qPCR. Shown here are the
expression levels of four candidates A) LUM B) LIPG C) LOXL2 and D) CTSB. The expression levels measured by qPCR are
shown in the left, while those from microarray are shown in the right. The expression values for qPCR were calculated using ΔΔ Ct
method using 18S for normalization. Microarray values represent normalized and preprocessed data that have been log
transformed. The plotted data represent mean ± S.E. Two-tailed student’s t-test was used for statistical analysis of qPCR data.
Statistically significant differences in expression are indicated with *. Similar trend of regulation was observed for data from both
techniques for these four genes. *, p ≤0.05; **, p≤0.01.
doi: 10.1371/journal.pone.0074993.g004
Isogenic Signature of Breast Cancer Subtypes
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in Figure 5A. Pairwise comparisons of deregulated genes
between breast cancer subtypes from the two GEO super
datasets are shown in Figure S2 (Table S4, S5).
Comparison of GEO datasets with data from MDA-MB-231
resulted in 4 up and 13 downregulated genes in TNBC vs.
HER2+ (Figure 5B, Table S6). Analogously, 11 genes each
were found to be up and downregulated in comparison with the
MDA-MB-468 data (Figure 5C, Table S7). Overlap of these two
comparisons provided two downregulated genes, GDF15 and
GPRC5A; however, there were no upregulated genes.
Additionally, we also compared our results with a published
mRNA sequencing based study of different breast cancer
subtypes from our lab [30]. Comparison of MDA-MB-231 cells
results with the sequencing data sets resulted in 56 genes that
showed the same deregulation pattern in TNBC as compared
to HER2+ samples (Figure 6A, Table S8a, b). Parallel
comparison with data from MDA-MB-468 cells resulted in 72
genes with same trend of regulation (Figure 6B, Table S8 c, d).
From these two comparisons, we found 10 common genes that
followed the same regulation pattern.
Discussion
We have established an isogenic model system for the
comparative study of TNBC and non-TNBC (HER2+) subtypes.
The reengineered non-TNBC cell lines express HER2
receptors at levels comparable to receptor-positive cell lines.
As a proof of functionality of transfected receptor, we observed
an effective downregulation of overexpressed HER2 in the
stable clones after treatment with Herceptin. Furthermore,
isogenic background of the stable cell lines made comparison
between different subtypes feasible without any generally
noticed variability of genetic background. To the best of our
knowledge, this is the first isogenic cell line model for
comparing two major breast cancer subtypes. Using our model
system, we have identified gene expression signatures that
differentiate TNBC and HER2+ breast cancer subtypes.
Our goal was to identify a genomic signature associated with
the status of HER2 in breast cancer and how their loss in
TNBC affects the expression of other genes. Using microarray
technology, we interrogated the expression levels of multiple
genes that changed as a result of expression of HER2 alone in
isogenic setting using two different cell lines. We have
characterized a signature of TNBC in comparison to HER2+,
non-TNBC subtype. In addition, we have also identified a
comprehensive list of all statistically significant deregulated
genes between TNBC and HER2+ cell line in isogenic
background. A survey of literature pointed out several
candidates from our studies to be in line with various published
studies, validating the merit of our study. We found that
Fibroblast Growth Factor Receptor 2 (FGFR2) and acyl-CoA
dehydrogenase, short/branched chain (ACADSB), which was
found to be upregulated in TNBC in a study by Turner et al. to
have higher expression in TNBC clones compared to two other
subtypes [31]. Similarly Cysteine-rich angiogenic inducer
61 (CYR61), that we found to be upregulated in TNBC
compared to HER2+ subtype, is overexpressed significantly in
TNBC. CYR61 is also significantly upregulated in invasive
breast cancer and considered as an important therapeutic
target for breast cancer [32]. From the list of molecules that are
positively correlated to HER2 status in breast cancer tumors
and cell lines from a study by Bertucci et al., we found two
candidates lysl oxidase (LOX) and fatty acid desaturase 2
(FADS2) with similar correlation in our data sets [33].
Candidates reported in this study could include molecules that
are affected by the downregulation of HER2 in TNBC, including
novel targets of HER2, and are important players in the
development of TNBC and its invasive phenotype.
One theory as to how TNBC might evolve is that in early
stages, breast tumor starts out as a hormone receptor positive
benign lesion that depends on hormones (e.g. estrogen) for its
growth and proliferation. During the course of its malignancy,
the tumor develops hormonal independence, gradually loses
the expression of estrogen receptor and becomes more
aggressive. However, the mechanism of downregulation of the
estrogen receptor is poorly studied due to lack of a suitable
model system [34]. Clark et al. studied down regulation of
estrogen receptor using wild type MCF-7 and its sublines that
lose their receptor expression and hormone dependence [35].
Differentially expressed genes between TNBC and HER2+
samples in our model system potentially constitute the gene
signature that changes as a result of tumor progression from
being receptor, HER2 in this case, positive to receptor null.
Similarly, since TNBC shows absence or low levels of HER2,
our data could point to negative regulators of the receptor
tyrosine kinase in TNBC. However, additional studies are
needed to validate these tentative conclusions and to gain a
mechanistic insight into the downregulation of the receptor. We
found several molecules with repressor functions like ERBB
receptor feedback inhibitor 1 (ERRFI1), grainyhead-like 1
(Drosophila) (GRHL1) and E3 ubiquitin-protein ligase RING2
(RNF2) upregulated in TNBC clones compared to other two
subtypes. It would be interesting to study if any of these are
responsible for the downregulation of HER2 receptors in
TNBC.
The overlap of gene expression signature from our cellular
model with microarray data sets from breast cancer patient
samples of corresponding subtypes increases the confidence
of our finding. Additionally it also provides an essential receptor
status related gene dataset with physiological significance for
further studies. This could be of high value as diagnostic and
therapeutic targets for TNBC.
Conclusion
Using an isogenic model system, we have shown that the
underlying molecular differences between various breast
cancer subtypes are evident at the level of gene expression.
Our findings point to key molecules and events that are
potentially linked to the biology of TNBC and explain how it
differs from HER2+ subtype. The deregulated genes potentially
represent the signature that changes as breast cancer
progresses into a more aggressive TNBC phenotype. Our
findings also exhibit how upregulation of a single gene could
lead to whole range of molecular changes in the isogenic cells.
Importantly, a portion of alterations in the expression levels in
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Figure 5.  Comparison of microarray data from isogenic clones and patient samples.  A) Flow diagram showing curation of
microarray patient sample data from GEO repository and compilation of two super datasets. B) Results from pairwise differential
expression comparison between TNBC and HER2+ve tumors in each of the super-datasets created from samples in GPL96 and
GPL570 microarray platforms. C) Venn Diagrams showing up and downregulated genes in each of the two pairwise comparison
between TNBC and HER2+ samples from isogenic clone data and the two GEO super-datasets. Various overlaps were seen in
each comparison.
doi: 10.1371/journal.pone.0074993.g005
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Figure 6.  Comparison of microarray data from isogenic clones and RNA-seq data from patient samples with similar breast
cancer subtypes.  A) Comparison of differentially expressed genes obtained from RNA-seq data from patient samples and
microarray data in A) MDA-MB-231 background B) MDA-MB-468 background. The overlap in the Venn diagram show common
genes between the comparisons and the number circled in red indicates the candidates that show same trend of regulation in both
microarray and RNA-seq dataset (shown as a heatmap).
doi: 10.1371/journal.pone.0074993.g006
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the model system also hold true in human TNBC and non-
TNBC HER2, suggesting the presence of an element of
isogenic signature within the generally noted heterogeneous
expression patterns. We provide an important dataset and a
model system for further exploration and testable hypothesis
generation. Further in depth studies are needed for confirming
our findings and using it for identifying cases of TNBC from
non-TNBC that would aid in tailoring subtype specific therapies.
Supporting Information
Figure S1.  Surface expression of transfected HER2 is
effectively downregulated upon 4D5 (Herceptin) treatment.
Confocal microscopy was used to determine the surface
expression of HER2 in isogenic clones in A) MDA-MB-231 B)
MDA-MB-468 backgrounds. One TNBC and two HER2 clones
in each cell line were treated with 10nM 4D5 after 24hr
starvation. Immunofluorescence staining was used for
examining HER2 expression (red) in the control and treated
cells. HER2 was expressed at a higher level in HER2 clones in
comparison to TNBC (pcDNA) clones. Treatment of the HER2
clones with 4D5 reduced the expression of HER2 similar to the
levels seen in the TNBC clones. These observations were
similar for clones in both cell lines.
(PPTX)
Figure S2.  Differential gene expression between pairwise
comparison of TNBC and non-TNBC (ER+ and HER2+)
samples from GEO datasets compiled from A) GPL96 and
B) GPL570 microarray platforms. Fold change of 1.5 and p
value 0.05 were used as cut-offs during the comparison. Top
boxes (purple) give the total number of deregulated genes in
each comparison. Meanwhile, boxes in red and green give a
breakdown of upregulated and downregulated genes
respectively.
(PPTX)
Table S1.  Number of samples from each datasets
belonging to TNBC and HER-2 positive subtypes included
in our super-datasets from A) GPL96 B) GPL570 platforms.
(DOCX)
Table S2.  Deregulated genes between pcDNA and HER2+
clones in MDA-MB-231 and MDA-MB-468 backgrounds.
(XLSX)
Table S3.  Top ten biological processes enriched in genes
deregulated in TNBC vs. HER2+ in MDA-MB-231 and MDA-
MB-468 cell lines.
(DOCX)
Table S4.  Deregulated genes in TNBC compared to HER2+
in GPL96 super-dataset.
(XLSX)
Table S5.  Deregulated genes in TNBC compared to HER2+
in GPL570 super-dataset.
(XLSX)
Table S6.  Overlap of deregulated genes in TNBC vs.
HER2+ in MDA-MB231 isogenic clones and two GEO
datasets (GPL96 and GPL570).
(XLSX)
Table S7.  Overlap of deregulated genes in MDA-MB-468
TNBC vs. HER2+ in isogenic clones and two GEO datasets
(GPL96 and GPL570).
(XLSX)
Table S8.  Overlap between deregulated genes in TNBC vs.
HER2+ in isogenic clones in MDA-MB-231 and MDA-
MB-468 cell lines and Patient RNA-seq data.
(XLSX)
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